CJC1295 (no DAC) Acetate: Lab Handling & Research Guidelines

CJC1295 (no DAC) acetate is a synthetic, DAC-free analogue of growth hormone-releasing hormone (GHRH) supplied by Aladdin Scientific (SKU M1529586) for in vitro and preclinical research into the somatotropic axis.

Product SKU

M1529586

Chemical Class

Synthetic GHRH analogue peptide (acetate salt)

DAC Modification

Absent — no Drug Affinity Complex; shorter plasma half-life than CJC-1295 with DAC

Primary Research Use

In vitro and preclinical studies of GH secretion and somatotropic signalling

Recommended Storage

−20 °C (long-term); avoid repeated freeze–thaw cycles

Solubility

Soluble in aqueous buffers (e.g., sterile water, PBS, 0.1% BSA in PBS); vortex gently

Product Overview and Mechanism of Action

CJC1295 (no DAC) acetate is a truncated, modified analogue of endogenous growth hormone-releasing hormone (GHRH 1–29). Unlike the DAC-bearing variant, this form does not contain a reactive maleimide group that covalently binds plasma albumin; consequently it exhibits a shorter circulating half-life more comparable to native GHRH, making it suitable for acute stimulation paradigms in research settings.

The peptide acts at the GHRH receptor (GHRHR) on anterior pituitary somatotrophs, stimulating adenylate cyclase via Gs proteins, elevating intracellular cAMP, and promoting pulsatile growth hormone (GH) release. Downstream effects studied in model systems include IGF-1 upregulation, promotion of lipolysis, and anabolic signalling. Aladdin Scientific supplies this compound exclusively for research and laboratory use; it is not approved for human therapeutic or diagnostic applications.

Reconstitution Protocol

Materials required: Sterile water for injection (WFI), phosphate-buffered saline (PBS, pH 7.4), or 0.1% bovine serum albumin (BSA) in PBS; low-binding microcentrifuge tubes; micropipettes.

1. Allow the lyophilised vial to equilibrate to room temperature (approximately 15–20 minutes) before opening to minimise moisture condensation.
2. Add the reconstitution solvent slowly down the inner wall of the vial. Do not inject directly onto the peptide cake.
3. Gently swirl or vortex at low speed until the material is fully dissolved. Avoid vigorous agitation that can cause foaming and peptide degradation.
4. If downstream assays require low protein backgrounds, use sterile water or PBS. Adding 0.1% BSA helps stabilise the peptide at low concentrations (<1 µg/mL) by reducing adsorption to tube surfaces.
5. Prepare working aliquots immediately after reconstitution. Store unused aliquots at −80 °C; avoid more than two freeze–thaw cycles.
6. Use reconstituted peptide within 1 month when stored at −20 °C, or within 1 week when stored at 4 °C.

Note: Specific reconstitution volumes and target concentrations should be determined by the investigator based on the experimental design. Typical stock concentrations in published GHRH analogue research range from 0.1 mg/mL to 1 mg/mL; however, confirm this against your assay requirements.

Storage, Stability, and Handling Precautions

Lyophilised form: Store at −20 °C in a desiccated environment, protected from light. Under these conditions, the lyophilised peptide is expected to be stable for at least 24 months from the date of manufacture when stored properly; however, users should verify stability with periodic quality checks.

Reconstituted solution: Peptide solutions are susceptible to proteolytic degradation, oxidation of methionine residues, and aggregation. To mitigate these risks:

• Aliquot into single-use volumes to avoid repeat freeze–thaw.
• Use low-protein-binding tubes and pipette tips.
• Minimise exposure to elevated temperatures and repeated light exposure.
• If aggregation is suspected, centrifuge at 10,000 × g for 5 minutes and use only the supernatant.

Safety: As a research chemical, handle in accordance with standard laboratory safety protocols. Wear appropriate PPE (gloves, lab coat, eye protection). Although CJC1295 (no DAC) acetate presents a low acute toxicity risk at research quantities, treat all peptides as potentially bioactive. Consult your institution's biosafety office and the applicable Safety Data Sheet (SDS) before use.

Research Applications and Experimental Considerations

CJC1295 (no DAC) acetate is principally used in the following research contexts:

• In vitro pituitary cell assays: Stimulation of GH release from primary somatotroph cultures or GH3 cell lines to study GHRHR signalling, second-messenger cascades, and receptor desensitisation.
• Preclinical animal studies: Acute GH secretagogue challenges in rodent models to assess somatotropic axis responsiveness; the absence of DAC facilitates time-resolved, pulsatile dosing paradigms.
• Peptide stability and pharmacokinetic research: Comparative studies examining how DAC modification alters half-life and receptor engagement.
• Combination studies: Co-administration with GHRP peptides (e.g., GHRP-2, GHRP-6) in preclinical models to examine synergistic GH release; researchers should design appropriate controls.

Experimental design notes: Because endogenous GHRH is pulsatile, baseline GH levels in animal models can be highly variable; adequate group sizes and time-matched sampling are essential. Peptide potency may vary between lots; inclusion of a positive control peptide standard in each experiment is recommended. All animal studies must comply with institutional IACUC/ethics committee approvals.

Quality, Purity, and Regulatory Status

Aladdin Scientific's CJC1295 (no DAC) acetate (SKU M1529586) is manufactured for research use only (RUO). Key quality attributes typically assessed for synthetic peptides of this class include:

• Purity: Assessed by reverse-phase HPLC; research-grade peptides in this category are commonly supplied at ≥95% purity. Refer to the Certificate of Analysis (CoA) provided with each lot for the actual purity value.
• Identity: Confirmed by mass spectrometry (MS); the observed molecular mass should be consistent with the theoretical molecular weight of the peptide sequence.
• Counterion: Acetate salt form; the acetate counterion does not contribute to biological activity.

Regulatory notice: This product is a research reagent and is not intended for human or veterinary therapeutic use, clinical trials, or diagnostic procedures. It is not an approved drug or medical device. Researchers are responsible for ensuring that their use complies with all applicable local, national, and institutional regulations, including those governing the use of peptide hormones and growth factors in research.

Frequently asked questions

What is the difference between CJC1295 with DAC and CJC1295 (no DAC)?

CJC1295 with DAC contains a reactive maleimide-based Drug Affinity Complex that covalently binds endogenous serum albumin, dramatically extending its plasma half-life to days. CJC1295 (no DAC) lacks this modification and therefore has a much shorter half-life closer to native GHRH (~30 minutes in rodents), making it preferable for acute, time-resolved stimulation experiments where prolonged receptor activation would confound results.

What solvent should I use to reconstitute CJC1295 (no DAC) acetate?

Sterile water for injection or phosphate-buffered saline (PBS, pH 7.4) are the most commonly used solvents. For experiments at very low peptide concentrations (below ~1 µg/mL), adding 0.1% BSA to the reconstitution buffer helps prevent adsorption losses to tube and pipette surfaces. Avoid organic solvents such as DMSO unless specifically validated for your application, as they can promote aggregation of hydrophilic peptides.

How should reconstituted CJC1295 (no DAC) acetate be stored and for how long?

After reconstitution, aliquot the peptide solution into single-use volumes and store at −80 °C for best stability. At −20 °C, use within one month; at 4 °C, use within one week. Avoid repeated freeze–thaw cycles, which accelerate aggregation and degradation. The lyophilised unreconstituted material should be stored at −20 °C in a dry, dark environment.

Is CJC1295 (no DAC) acetate suitable for human use or clinical trials?

No. Aladdin Scientific's CJC1295 (no DAC) acetate (SKU M1529586) is supplied exclusively for in vitro and preclinical research purposes. It is not approved by any regulatory authority for human therapeutic, diagnostic, or clinical trial use, and must not be administered to humans or animals outside a properly approved research framework.

How do I verify the purity and identity of my CJC1295 (no DAC) acetate lot?

Each lot is accompanied by a Certificate of Analysis (CoA) that reports HPLC purity and mass spectrometry identity data specific to that batch. Request the CoA from Aladdin Scientific at the time of purchase or download it using the lot number from our website. If you require additional characterisation data (e.g., amino acid analysis, endotoxin testing), please contact our technical support team.

References

1. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. doi:10.1210/jc.2006-1702
2. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1995
3. Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. doi:10.1152/ajpendo.00201.2006

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.